Please assess the completion status of the following clinical trial:

Trial Title: MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum~* Patients receiving bevacizumab must have tumor tissue available for immunohistochemical analysis~  * Formalin-fixed, paraffin-embedded tissue from previous biopsy or surgical resection is sufficient~* Measurable disease, defined by RECIST as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm by conventional techniques (i.e., CT or MRI)~  * CEA elevation alone is insufficient for study entry~* No known brain metastases~PATIENT CHARACTERISTICS:~Criteria for all patients~* ECOG performance status 0-1~* Life expectancy \> 3 months~* Granulocytes ≥ 1,500/mL~* Platelet Count ≥ 100,000/mL~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* AST ≤ 5 times ULN~* Urine protein:creatinine ratio ≤ 1.0 at screening~* Patients with other prior malignancies are eligible, provided they have been treated with curative intent and have no evidence of recurrence~* Not pregnant or nursing~* Negative pregnancy test~* No contraindications to MRI, including any of the following:~  * Hypersensitivity to gadolinium~ * Metallic device, including pacemaker, non-MRI compatible aneurysm clip, other non-MRI-compatible mechanical and/or electrical device, or metallic fragments~ * Severe claustrophobia~Additional criteria for patients receiving bevacizumab:~* No significant traumatic injury within the past 28 days~* No serious nonhealing wounds, ulcers, or bone fractures~* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months~* No myocardial infarction, unstable angina, or cerebrovascular accident within the past 6 months~* No clinically significant peripheral vascular disease~* No New York Heart Association class II-IV congestive heart failure~* Patients with pre-existing hypertension should be on a stable antihypertensive regimen with blood pressure ≤ 150/100 mm Hg at study entry~PRIOR CONCURRENT THERAPY:~Criteria for all patients~* Prior adjuvant treatment including oxaliplatin allowed~* No prior bevacizumab~* At least 14 days since prior radiotherapy and recovered~* More than 6 months since prior chemotherapy~* No other concurrent investigational agents~Additional criteria for patients receiving bevacizumab:~* At least 28 days since prior major surgical procedure or open biopsy~* At least 7 days since prior minor surgical procedure (e.g., fine-needle aspirations or core biopsies)~* No anticipation of need for a major surgical procedure during study treatment~* Concurrent oral or parenteral anticoagulation therapy allowed provided dose is stable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
- FOLFOX alone (control) (Type: ACTIVE_COMPARATOR): Patients receive FOLFOX as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).